Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone breath-activated inhalation - IVAX

Drug Profile

Beclometasone breath-activated inhalation - IVAX

Alternative Names: Beclazone 250 Easi-Breathe; Beclazone Easi-Breathe; Beclometasone breath-activated inhalation - Baker Norton; Beclometasone CFC-free Easi-Breathe; Beclomethasone breath-activated inhalation - Baker Norton; Beclomethasone breath-activated inhalation - IVAX; Beclomethasone CFC-free Easi-Breathe

Latest Information Update: 19 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IVAX Laboratories
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 01 Mar 2010 Withdrawn for Asthma in United Kingdom (Inhalation)
  • 01 Jul 2009 Withdrawn for Asthma in Mexico (Inhalation)
  • 01 Jan 2008 Withdrawn for Asthma in Czech Republic (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top